About: Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 06 April 2009

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2009 (ast) наукова стаття, опублікована у квітні 2009 (uk) scientific article published on 06 April 2009 (en) مقالة علمية نشرت في 06 أبريل 2009 (ar)
publication date	wds:Q37435425-A51BCE0C-7EAD-41E3-A86D-AD1C0E7350C2
publication date	2009-04-06 00:00:00Z (xsd:dateTime)
author name string	wds:Q37435425-0D1FC0E4-CDD8-4315-A72F-001A2093F600 wds:Q37435425-1E904A6D-1B4F-45EE-90A0-17A61DC2E2E1 wds:Q37435425-780251A6-7DC4-47F2-B09D-44A418C4D74F wds:Q37435425-97A0E5FC-408B-4991-97EF-21EE7DE61CD0 wds:Q37435425-9889C349-4EB7-4AA1-9890-9D794B6B2760 wds:Q37435425-BCAE3F3F-9D55-4296-8373-3CEFD78BAE4A wds:Q37435425-E17F06CC-E7D1-4F09-945F-E2188A14C33B
author name string	Francesco Perrone Jane Bryce Gianfranco De Feo Maria Carmela Piccirillo Antonia Del Giudice Ermelinda De Maio Fabiano Falasconi
rdfs:label	Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. (en) Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. (nl) Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. (ast)
skos:prefLabel	Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. (en) Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. (nl) Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. (ast)
name	Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. (en) Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. (nl) Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. (ast)
author	wds:Q37435425-13B6DAE4-1E2C-42D1-8A47-1019A072FED5 wds:Q37435425-42A13088-1EA1-4CB1-974F-6B27F6E856FC wds:Q37435425-D5C4885F-75D3-405A-8B48-B42F66FCDD8C
author	Alessandro Morabito Massimo Di Maio Nicola Normanno
title	wds:Q37435425-1B9CCA40-7776-4975-95AB-7C105E0E3054
title	Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions (en)
page(s)	wds:Q37435425-E85908B1-F3B5-4E6F-B37C-5F280072D993
page(s)	378-390
instance of	wds:Q37435425-3758e735-a9ee-4cf5-ab8d-478988c4deae wds:Q37435425-82D1A97A-A51A-4392-8DDF-2EAEDE8F49EF
instance of	review article scholarly article
main subject	wds:Q37435425-377182D3-6F25-477E-8D2E-1549FDBB96B4 wds:Q37435425-D9E4D579-84A9-49E2-B098-2E7A29FA9B26
main subject	endothelium wd:Q7914515
PubMed ID	wds:Q37435425-EB915E95-31A1-4D3B-BA40-C8CB04905B63
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/19349511
PubMed ID	19349511
published in	wds:Q37435425-21FA1740-5C0C-4A06-BFB9-C686356DA2D2
published in	Oncologist
issue	wds:Q37435425-02A8CA59-3B03-43E1-B08C-CAD8295B4905
volume	wds:Q37435425-78A2FDC1-56DC-453F-BC51-830B38288A03
issue	4
volume	14
DOI	wds:Q37435425-BC543EED-E2A5-4E27-B40D-A035FFCF1646
DOI	http://dx.doi.org/10.1634/THEONCOLOGIST.2008-0261
DOI	10.1634/THEONCOLOGIST.2008-0261
Fatcat ID	wds:Q37435425-56D2323E-EBB1-45BE-A191-40BAE0A8AEEE
Fatcat ID	release_bnu3nnj3mfe73pnb7v776npjmu
ResearchGate publication ID	wds:Q37435425-2A333137-B774-448B-BC7B-40FCB4E1C627
ResearchGate publication ID	24260559
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q37435425
is cites work of	Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials Comparison of effects of anti-angiogenic agents in the zebrafish efficacy-toxicity model for translational anti-angiogenic drug discovery ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors Integration of biomarkers including molecular targeted therapies in head and neck cancer Dual inhibition of vascular endothelial growth factor receptor and epidermal growth factor receptor is an effective chemopreventive strategy in the mouse 4-NQO model of oral carcinogenesis Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Axitinib for the management of metastatic renal cell carcinoma XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment Identifying therapeutic targets in a combined EGFR-TGFβR signalling cascade using a multiscale agent-based cancer model Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Dissection of the RET/β-catenin interaction in the TPC1 thyroid cancer cell line. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress? The novel VEGF receptor 2 inhibitor YLL545 inhibits angiogenesis and growth in breast cancer SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer Targeted therapies for gastric cancer: current status The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer. Discovering Molecular Targets in Cancer with Multiscale Modeling Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software